OakChart

vTv Therapeutics Inc

VTVTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

21.47+0.47 (2.24%)
2026-11-12 05:09 CET
Market cap
84.89 USD m
Revenue, TTM
36.84 USD m
Net income, TTM
-7.68 USD m
Free cash flow, TTM
-21.73 USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

VTVT against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.0035.00108K215KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VTVTclose 21.4720-day 24.8250-day 28.57200-day 33.0321.4752w low

51.2% under the 52-week high of 44.00 on 6 Jan 2026. 52-week low 20.56 on 6 Nov 2026. Last 15 sessions, 36.4% high to low

Volume 0.31× normal · the line is the 50-bar volume average

Profile

VTVT
52-week range, 4% of the way up
20.5644.00

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Employees26
IPOJul 30, 2015
Beta0.29
ATR, 14d1.45
Rel volume0.31
Short float7.06%
Insider own47.93%
Inst own31.17%

Snapshot

6 groups

Valuation

Index-
Market Cap84.89M
Enterprise Value7.73M
Income-7.68M
Sales36.84M
Book/sh17.37
Cash/sh19.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees26
IPOJul 30, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S2.30
P/B1.24
P/C1.10
P/FCF-
EV/EBITDA-
EV/Sales0.21
Quick Ratio11.19
Current Ratio11.19
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-3.95
EPS next Q-1.08
EPS this Y50.31%
EPS next Y-148.34%
EPS next 5Y-10.80%
EPS past 3/5Y32.12% 14.99%
Sales past 3/5Y- -
EPS Y/Y TTM81.41%
Sales Y/Y TTM216600.00%
EPS Q/Q13.37%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.13.76% -

Ownership

Insider Own47.93%
Insider Trans0.00%
Inst Own31.17%
Inst Trans9.78%
ROA-8.62%
ROE-10.95%
ROIC-11.02%
Gross Margin99.99%
Oper. Margin-29.80%
Profit Margin-20.84%
SMA20-13.49%
SMA50-24.86%
SMA200-35.00%
Trades-

Technical

Shs Outstand4.01M
Shs Float2.06M
Short Float7.06%
Short Ratio3.82
Short Interest0.15M
52W High44.00 -51.20%
52W Low20.56 4.43%
Volatility6.97% 5.69%
ATR (14)1.45
RSI (14)27.57
Beta0.29
Rel Volume0.31
Avg Volume38.03K
Volume11,737

Performance

Perf Week-10.65%
Perf Month-23.95%
Perf Quarter-30.41%
Perf Half Y-32.20%
Perf YTD-46.31%
Perf Year-26.22%
Perf 3Y51.62%
Perf 5Y-64.22%
Perf 10Y-89.11%
Recom1.00
Target Price57.38
Prev Close21.00
Price21.47
Change %2.24%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Jun 30, 2026InitiatedRRodman & RenshawBuy$67+212.1%
Mar 12, 2026InitiatedEEvercore ISIOutperform$44+104.9%
Jan 23, 2026InitiatedRRoth CapitalBuy$58+170.1%
Jan 05, 2026InitiatedTTD CowenBuy$67+212.1%
Nov 19, 2025InitiatedBBTIG ResearchBuy$40+86.3%
May 30, 2019InitiatedHH.C. WainwrightBuy
Apr 10, 2018DowngradeSStifelBuy → Hold$12 → $1-95.3%
Mar 08, 2018InitiatedRROTH CapitalBuy$17-20.8%
Feb 08, 2018InitiatedNNorthland CapitalOutperform$28+30.4%
Sep 26, 2016InitiatedHH.C. WainwrightBuy$13-39.5%

Peers

Mkt cap
TickerCompanyMkt cap
BMEABiomea Fusion Inc44.28M
LXRXLexicon Pharmaceuticals Inc832.59M
RZLTRezolute Inc393.69M
SANASana Biotechnology Inc686.16M
GUTSFractyl Health Inc11.68M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
VRTXVertex Pharmaceuticals Inc138.69B
ENTXEntera Bio Ltd560.73M
MBXMBX Biosciences Inc2.87B
AMLXAmylyx Pharmaceuticals Inc4.09B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • VTv Therapeutics: Q3 Earnings Snapshot (Associated Press) -9.53%
  • vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems (GlobeNewswire)
  • vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 (GlobeNewswire)
  • vTv Therapeutics stock jumps on FDA orphan drug status (Investing.com)
  • vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease (GlobeNewswire)
  • vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 (GlobeNewswire)
  • vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) (GlobeNewswire)
  • vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • vTv Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
  • vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • VTv Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.940-1.090-0.9400.000.007
2026Q22026-08-06-1.050-0.970-1.0520.000.335
2026Q12026-05-131.6500.2101.64936.8420.006
2025Q42026-03-10-0.580-1.088-0.5750.000.005
2025Q32025-11-06-1.080-0.980-1.0800.000.002
2025Q22025-08-12-0.920-0.825-0.9180.000.002
2025Q12025-05-15-0.770-0.815-0.7740.000.002
2024Q42025-03-20-0.550-0.870-0.5520.020.001
2024Q32024-11-12-0.880--0.8770.00--
2024Q22024-08-08-0.810--0.8091.00--
2024Q12024-05-09-1.170--1.1751.00--
2023Q42024-03-13-66.800--1.6680.01--
2023Q32023-11-09-128--3.2660.01--
2023Q22023-08-11-2.800-2.800-2.7580.010.001
2023Q12023-05-11-2.400-3.800-2.2080.000.002
2022Q42023-03-06-2.400-2.532-2.3290.010.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-14.800-18.000-23.6542.764.03
2020FY-6.800-10.400-7.2126.411.66
2021FY-5.600-6.800-8.5544.014.33
2022FY-10.400-10.800-10.2382.022.01
2023FY-9.710--9.7122.02-
2024FY-3.200-3.650-3.1991.021.00
2025FY-3.200-4.146-3.2000.000.00
2026FY--1.590--36.87
2027FY--3.949--0.80
2028FY--4.353--1.60
2029FY--4.942--6.18
2030FY--3.012--46.62

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-064000.000.000.00
2026Q4S2026-11-054000.000.000.00
2026Q4S2026-08-064000.000.000.00
2026Q4S2026-05-143000.000.000.00
2026Q4S2026-03-112000.000.000.00
2026Q4S2026-01-213000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4S2025-11-082000.000.000.00
2026Q4S2025-11-072000.000.000.00
2026Q4R2026-11-06310-1.09-1.32-0.89
2026Q4R2026-11-05300-1.15-1.32-0.89
2026Q4R2026-10-20300-1.15-1.32-0.89

Estimate history

EPS, annual-66.8-27.793-23.654-7.212-8.554-10.238-9.712-3.199-3.202-0.9133
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.877-0.552-0.774-0.918-1.08-0.5751.649-1.052-0.935
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.29112.4342.7646.4144.0052.01801.017036.84
Period201720182019202020212022202320242025TTM
Sales, quarterly00.017000036.83900
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.2420.5091.0231.3511.6742.0372.0852.6123.9394.011
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.6122.6122.6122.6173.9383.9393.9393.9394.011
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue36.840.001.020.002.024.006.412.7612.43
Cost of Goods Sold Incl. D&A0.010.020.090.090.090.09---
Gross Profit36.83-0.020.93-0.091.933.92---
Selling, General and Administrative Excl. Other47.8132.7925.1125.4124.4725.5818.1723.6232.04
Research and Development29.1817.8411.4613.5112.2713.2310.9215.0823.04
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.98-32.81-24.18-25.50-22.54-21.66-11.85-20.89-19.82
Interest Expense0.000.010.000.010.010.010.691.833.29
Unusual Expense-0.120.030.153.982.67-4.060.27-0.830.64
Net Income Before Taxes-7.68-31.08-22.61-25.97-24.87-17.62-12.80-21.84-23.64
Income Taxes0.000.000.100.000.200.120.000.100.20
Consolidated Net Income-7.68-31.08-22.70-25.97-25.07-17.73-12.80-26.81-24.58
Net Income From Continuing Operations-7.68-26.97-18.46-20.25-19.16-12.99-8.50-17.91-8.65
Net Income-7.68-26.97-18.46-20.25-19.16-12.99-8.50-17.91-8.65
EPS (Recurring)-0.62-3.20-3.18-8.37-9.24-10.42-7.05-24.42-26.36
EPS (Basic, Before Extraordinaries)-0.62-3.20-3.20-9.71-10.24-8.55-7.21-23.65-27.79
EPS (Diluted)-0.91-3.20-3.20-9.71-10.24-8.55-7.21-23.65-27.79
EBITDA-10.97-32.79-24.09-25.41-22.45-21.57-11.76-20.85-19.61
Non-Operating Income (Expense)3.181.761.733.530.350.000.010.050.11
Other After Tax Adjustments0.000.000.000.000.000.000.00-4.87-0.74
Stock Option Compensation Expense6.113.772.181.581.001.721.011.112.11
Price To Sales Ratio10.40-78.36-24.5915.0913.6718.632.65
Gross Margin99.99-91.25-95.4497.78---
Operating Margin-29.80--2,377.58--1,116.95-540.87-184.78-755.86-159.43
Net Margin-20.84--1,815.34--949.65-324.27-132.51-648.08-69.57
Shares Outstanding4.013.942.612.082.041.671.351.020.51
Market Capitalization84.8984.8936.0723.4354.0166.61100.5369.5653.92

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.0036.840.000.000.000.000.02
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.010.02
Gross Profit-0.00-0.0036.84-0.00-0.00-0.00-0.01-0.01
Selling, General and Administrative Excl. Other12.4313.9313.577.8810.707.726.494.89
Research and Development7.538.778.983.917.024.102.822.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.43-13.9323.26-7.88-10.70-7.72-6.50-4.89
Interest Expense0.000.000.000.000.010.000.000.00
Unusual Expense-0.07-0.06-0.030.050.01-0.050.03-0.02
Net Income Before Taxes-11.62-13.0524.13-7.14-10.35-7.38-6.22-4.44
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-11.62-13.0524.13-7.14-10.35-7.38-6.22-4.44
Net Income From Continuing Operations-11.62-13.0524.13-7.14-8.70-6.05-5.09-3.63
Net Income-11.62-13.0524.13-7.14-8.70-6.05-5.09-3.63
EPS (Recurring)-0.94-1.061.65-0.57-1.08-0.92-0.77-0.55
EPS (Basic, Before Extraordinaries)-0.94-1.051.94-0.58-1.08-0.92-0.77-0.55
EPS (Diluted)-0.94-1.051.65-0.58-1.08-0.92-0.77-0.55
EBITDA-12.43-13.9323.26-7.88-10.70-7.72-6.49-4.87
Non-Operating Income (Expense)0.730.810.840.800.360.290.310.43
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.971.731.391.021.010.930.810.65
Price To Sales Ratio10.4012.6815.76-11,065.075,812.126,706.7689.38
Gross Margin--100.00-----29.41
Operating Margin--63.15-----28,776.47
Net Margin--65.51-----21,376.47
Shares Outstanding4.013.943.943.943.942.622.612.61
Market Capitalization84.89148.29156.21157.4861.1139.2645.2436.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments88.9336.759.4512.1313.415.751.781.6811.92
Short Term Receivables0.000.060.1012.420.060.160.010.008.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.961.301.112.552.011.311.061.790.44
Total Current Assets89.8938.1110.6627.0915.497.212.843.4720.36
Net Property, Plant & Equipment0.000.150.360.560.680.851.000.070.28
Total Investments and Advances0.000.000.005.599.176.724.984.984.98
Intangible Assets-0.000.000.000.000.000.000.000.00
Other Assets0.010.000.000.000.140.000.440.042.29
Total Assets89.9038.2711.0233.2425.4714.799.278.5627.92
Short Term Debt Incl. Current Port. of LT Debt0.000.170.360.380.440.246.289.384.27
Accounts Payable1.130.944.082.461.881.932.237.702.27
Other Current Liabilities5.514.096.184.876.184.234.871.7520.39
Total Current Liabilities6.645.2010.627.718.506.3913.3818.8426.93
Long Term Debt0.000.000.170.340.490.680.836.3315.32
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities18.8218.7718.7819.351.263.933.893.765.28
Total Liabilities25.4623.9629.5727.4010.2511.0018.1128.9347.52
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity64.4412.20-24.68-10.74-9.74-80.10-49.02-82.85-151.05
Total Shareholders Equity64.4412.20-24.68-10.74-9.74-80.10-49.02-82.85-151.05
Accumulated Minority Interest0.002.106.1316.5824.9683.8940.1862.48131.44
Total Equity64.4414.30-18.555.8415.223.79-8.84-20.37-19.61
Total Liabilities & Stockholders Equity89.9038.2711.0233.2425.4714.799.278.5627.92
Book Value Per Share16.364.67-11.84-5.27-5.82-59.28-47.92-162.88-623.31
Tangible Book Value Per Share16.364.67-11.84-5.27-5.82-59.28-47.92-162.88-623.31
Full-Time Employees26231613925265256
Price to Book Ratio1.242.40-0.93-4.30-6.84-1.26-1.42-0.65-0.43
Return on Assets-42.09-74.92-91.51-65.28-64.51-70.66-200.99-47.43-39.18
Return on Equity-70.40--------
Return on Invested Capital-41.86-151.34-------
Quick Ratio13.547.341.003.521.821.130.210.180.76
Current Ratio13.547.341.003.521.821.130.210.180.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-7.68-31.08-22.70-25.97-25.07-17.73-12.80-21.94-23.84
Depreciation0.010.020.090.090.090.090.090.040.22
Other Funds (Non Cash)6.064.312.752.974.35-0.81-2.590.944.32
Funds from Operations-1.61-26.75-19.87-22.91-20.63-18.46-15.29-20.96-19.31
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-20.111.89-5.444.395.380.04-2.71-2.05-7.54
Cash from Operating Activities-21.73-24.86-25.31-18.52-15.25-18.42-18.00-23.02-26.86
Capital Expenditures0.000.000.000.00-0.020.000.00-0.07-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.310.01
Purchase or Sale of Investments0.000.000.004.400.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.004.400.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.004.40-0.020.000.000.240.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.7277.4952.8012.0314.7926.8024.4332.9421.50
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.7277.4952.8012.0314.7926.8024.4332.9421.50
Proceedsfrom Stock Options0.3977.482.4612.0314.7926.7624.4332.9421.50
Issuance or Reduction of Debt, Net-0.33-0.39-0.19-0.60-0.81-0.71-4.96-10.07-4.89
Change in Long Term Debt-0.33-0.39-0.19-0.60-0.81-0.71-4.96-10.07-4.89
Issuance of Long Term Debt0.000.000.000.000.000.000.500.500.50
Reduction of Long Term Debt-0.33-0.39-0.19-0.60-0.81-0.71-5.46-10.57-5.39
Net Financing Active Other Cash Flow0.00-0.050.000.000.000.000.000.000.00
Other Financing Activities Uses0.00-0.050.000.000.000.000.000.000.00
Cash from Financing Activities0.3977.0552.6111.4313.9826.0919.4722.8716.61
Net Change in Cash-21.3452.1927.30-2.68-1.297.671.470.09-10.24
Free Cash Flow-21.73-24.86-25.31-18.52-15.27-18.42-18.00-23.09-26.86
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments77.1686.6498.0988.9398.5025.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.440.950.720.960.950.45
Total Current Assets78.6087.5998.8189.8999.4626.37
Net Property, Plant & Equipment0.000.000.000.000.040.07
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets----0.000.00
Other Assets0.000.000.010.010.000.00
Total Assets78.6187.5998.8189.9099.4926.45
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.360.08
Accounts Payable7.026.996.826.569.805.22
Other Current Liabilities0.000.030.060.08-0.00-0.00
Total Current Liabilities7.027.026.886.6410.165.29
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.901.941.9718.8218.7918.75
Total Liabilities8.928.968.8525.4628.9524.04
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity69.6978.6389.9664.4470.542.76
Total Shareholders Equity69.6978.6389.9664.4470.542.76
Accumulated Minority Interest0.000.000.000.000.00-0.36
Total Equity69.6978.6389.9664.4470.542.40
Total Liabilities & Stockholders Equity78.6187.5998.8189.9099.4926.45
Book Value Per Share17.3719.9622.8416.3617.911.06
Tangible Book Value Per Share17.3719.9622.8416.3617.911.06
Full-Time Employees---26--
Price to Book Ratio1.241.652.422.2322.134.95
Return on Assets-8.62-8.343.44-42.09-32.90-53.64
Return on Equity-10.95-11.694.60-70.40-54.87-203.31
Return on Invested Capital-16.67-16.6026.83-11.08-12.33-218.90
Quick Ratio11.1912.4814.3613.549.794.98
Current Ratio11.1912.4814.3613.549.794.98

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-11.62-13.0524.13-7.14-10.35-7.38
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)1.891.661.351.151.440.86
Funds from Operations-9.73-11.3925.49-5.99-8.90-6.51
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.46-0.05-16.34-3.264.071.42
Cash from Operating Activities-10.19-11.449.15-9.25-4.83-5.09
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.710.000.000.0177.480.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.710.000.000.0177.480.01
Proceedsfrom Stock Options0.390.000.000.0077.480.00
Issuance or Reduction of Debt, Net0.000.000.00-0.33-0.060.00
Change in Long Term Debt0.000.000.00-0.33-0.060.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.33-0.060.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.05
Other Financing Activities Uses0.000.000.000.000.00-0.05
Cash from Financing Activities0.710.000.00-0.3277.41-0.04
Net Change in Cash-9.48-11.449.15-9.5772.58-5.14
Free Cash Flow-10.19-11.449.15-9.25-4.83-5.09

Revenue breakdown

Pharmaceutical Preparations2024: 1.02M
United States2024: 1.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.06%0.1M2.1M48.83K
2026-10-156.96%0.1M2.1M64.52K
2026-09-307.61%0.2M2.1M70.71K
2026-09-157.78%0.2M2.1M74.70K
2026-08-317.95%0.2M2.1M74.34K
2026-08-148.10%0.2M2.1M72.24K
2026-07-318.13%0.2M2.0M61.77K
2026-07-158.44%0.2M2.0M53.77K
2026-06-308.02%0.2M2.0M52.57K
2026-06-157.77%0.2M2.0M48.54K
2026-05-297.71%0.2M2.0M58.39K
2026-05-157.09%0.1M2.0M56.49K
2026-04-306.71%0.1M2.0M54.91K
2026-04-154.40%0.1M2.6M44.97K
2026-03-313.22%0.1M2.6M41.18K
2026-03-132.59%0.1M2.6M34.87K
2026-02-272.24%0.1M2.6M20.86K
2026-02-131.99%0.1M2.6M18.55K
2026-01-301.24%0.0M2.6M15.63K
2026-01-151.21%0.0M2.6M14.02K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-08SCHEDULE 13G/ASEC
2026-10-068-KCurrent report2026-10-01SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-29SCHEDULE 13G/ASEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-06-10DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-13424B2SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-16SCHEDULE 13G/ASEC
2026-03-27SCHEDULE 13GSEC
2026-03-108-KCurrent report2026-03-10SEC
2026-03-108-KCurrent report2026-03-10SEC
2026-03-1010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-268-KCurrent report2026-02-26SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-17SEC
2026-02-184Statement of changes in beneficial ownership of securities2026-02-17SEC
2026-02-028-KCurrent report2026-01-30SEC
2025-12-198-KCurrent report2025-12-19SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Samsara BioCapital, LLC7.58%
MILLENNIUM MANAGEMENT LLC6.85%
FMR LLC6.59%
Siren, L.L.C.4.14%
BAKER BROS. ADVISORS LP3.77%
VANGUARD CAPITAL MANAGEMENT LLC2.40%
Trails Edge Capital Partners, LP2.16%
Aisling Capital Management LP1.27%
MARSHALL WACE, LLP1.00%
GEODE CAPITAL MANAGEMENT, LLC0.62%

Funds

Fund% owned
Select Biotechnology Portfolio6.59%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.54%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Fidelity Extended Market Index Fund0.35%
iShares Micro-Cap ETF0.18%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.11%
Invesco NASDAQ Future Gen 200 ETF0.08%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.04%
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. VTVT. Cached 15 minutes.

Some panels did not load: insider.